Amgen and Kirin Holdings have agreed that Kirin-Amgen, a joint venture between the two companies, will redeem Kirin’s shares in the joint venture for $780 million and, as a result, Kirin-Amgen will become a wholly owned subsidiary of Amgen.

Kirin-Amgen was established in 1984 as a 50-50 joint venture between Amgen and Kirin to fund the development of Amgen’s anemia drug, Epogen (epoetin alfa). Over time, the scope of the collaboration was expanded to include additional products: Neupogen (filgrastim), Neulasta (pegfilgrastim), Aranesp (darbepoetin alfa), Nplate (romiplostim), and brodalumab. Kirin-Amgen holds the intellectual property for each of these products and, in exchange for royalty rights, licensed the associated marketing rights in certain Asian countries to Kyowa Hakko Kirin (KHK), Kirin’s pharmaceutical subsidiary, and in other territories to Amgen.

With the joint venture now becoming a subsidiary of Amgen, the Kirin-Amgen joint venture will pay $780 million to Kirin. Amgen will make additional payments to Kirin upon the occurrence of certain sales (valued by Amgen at approximately $30 million). As sole shareholder of Kirin-Amgen, Amgen will own the product rights and remaining cash held by Kirin-Amgen. License agreements between Kirin-Amgen and KHK in certain Asian territories will remain in place. The transaction will be effective upon the fulfillment or waiver of certain conditions contained in the agreement, including the receipt of all necessary approvals from governmental authorities.

The transaction is expected to close during either the fourth quarter of 2017 or the first quarter of 2018.

Source: Amgen